Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis – Influence on IP-10, TNF-α and MCP-1

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2013-05, Vol.62 (2), p.290-296
• Main Authors: Klinghammer, Lutz, Urschel, Katharina, Cicha, Iwona, Lewczuk, Piotr, Raaz-Schrauder, Dorette, Achenbach, Stephan, Garlichs, Christoph D.
• Format: Article
• Language: English
• Subjects: Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; anti-inflammatory activity; Atherosclerosis; Atherosclerosis - drug therapy; Benzimidazoles - therapeutic use; Benzoates - therapeutic use; blood pressure; Blood Pressure - drug effects; blood serum; calcification; Chemokine CCL2 - blood; Chemokine CXCL10 - blood; Chemokines; computed tomography; coronary artery disease; Coronary Artery Disease - drug therapy; coronary vessels; Cytokines; Female; Humans; hypertension; Hypertension - drug therapy; Inflammation - drug therapy; Interleukin-6 - blood; Male; Middle Aged; patients; Risk factors; Telmisartan; Tumor Necrosis Factor-alpha - blood
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2013.02.001

► Hypertension is a prominent cause for coronary artery disease and associated with inflammation. ► Telmisartan has well-known antihypertensive and less-known anti-inflammatory effects. ► In hypertensive patients telmisartan only selectively affects cytokines/chemokines. ► We detected a hypothetic biphasic association between coronary artery calcification and MCP-1. ► TNF-α, IP-10 and MCP-1 could play a role in the progression of atherosclerosis. Hypertension is one of the most prominent risk factors for coronary artery disease (CAD). Treatment of hypertension is therefore important for reducing cardiovascular events and the progression of atherosclerosis. Several treatment strategies are common in clinical practice for example the use of ACE-blockers or angiotensin receptor II blockers (ARBs), so called sartans. Telmisartan, belonging to the class of ARBs, was shown to exert anti-inflammatory effects besides the blood pressure lowering. In this work, two separate substudy groups of hypertensives were compared. 16 patients with arterial hypertension have been treated with telmisartan (initial 40mg Kinzalmono®) for 7.3±4.4months. The telmisartan group was compared to a matched control group including 31 hypertensive patients without telmisartan treatment with a follow up period of 1.9±0.5years. Serum samples from the beginning and the end of follow up were analyzed with Luminex® technology for 26 cytokines and chemokines. The baseline scores of coronary artery calcification (CAC) were gathered by multislice detector computer tomography. After 7months of telmisartan treatment and 2years in control patients most of the measured analytes did not change significantly. MCP-1 (P=0.001; P